Frontiers in pharmacology
Cure8 research brief
Why This Matters
Mitochondrial dysfunction may contribute to IBD symptoms and disease progression; therapies that protect or restore mitochondrial function could become future treatment strategies. People interested in complementary or mechanism-focused research (including TCM-derived compounds) may find this review relevant.
Who Should Pay Attention
Researchers studying IBD mechanisms, clinicians interested in emerging therapeutic targets, and patients or caregivers curious about preclinical work on complementary/TCM approaches.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This review highlights mitochondrial dysfunction as an important factor in IBD pathogenesis and surveys preclinical evidence that active components from Traditional Chinese Medicine can affect mitochondrial functions—such as energy metabolism, oxidative stress, mitophagy, dynamics, and biogenesis—and interact with the gut microbiota–mitochondria axis.
The article focuses on mechanistic and preclinical research; it notes that clinical validation and target-specific pharmacology for TCM approaches are limited. The review offers conceptual pathways and potential therapeutic avenues rather than confirmed clinical treatments.
If you are curious about mitochondrial-targeted strategies or complementary therapies, this review organizes current laboratory and animal-model findings and suggests directions for future research and clinical studies.
Keep In Mind
The article is a review based on preclinical and mechanistic studies; it does not provide robust clinical trial evidence. Interpret findings as hypothesis-generating rather than ready-for-clinic. Cure8 did not verify individual study quality beyond the abstract.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationFrontiers in pharmacology
AuthorsZeng L, Huang Y, Ke J +4 more
Study typeReview, journal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedJul 9, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Lactiplantibacillus plantarum as a multifunctional probiotic for inflammatory bowel disease: Mechanisms, synbiotic strategies, and delivery systems.
People with IBD may be interested because the review describes a probiotic (L. plantarum) and synbiotic approaches that could influence gut inflammation, barrier function, and microbiota—areas directly relevant to IBD...
Microplastics, Gut Dysbiosis, and Inflammatory Pathways in Ulcerative Colitis.
If environmental microplastics contribute to gut dysbiosis and mucosal inflammation, this could help explain environmental triggers of ulcerative colitis and point toward prevention or microbiome-targeted interventions.
FUT2-mediated α1,2-fucosylation in inflammatory bowel disease: mechanisms and translational potential.
FUT2 connects genetics, mucosal sugars, and the gut microbiome — pathways that could help explain why some people with IBD have different microbiomes or disease risk. If validated in trials, FUT2-targeted or...